Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05263375
Other study ID # INVL21-02-BE
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2023
Est. completion date June 1, 2025

Study information

Verified date March 2022
Source Innovalve Bio Medical Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to evaluate the safety and performance of the Innovalve mitral valve replacement system


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date June 1, 2025
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Clinically significant, symptomatic mitral regurgitation - High risk for open-heart surgery - Meets anatomical criteria Exclusion Criteria: - Unsuitable anatomy - Patient is inoperable - EF <30%

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Innovalve TMVR system
Innovalve TMVR system

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Innovalve Bio Medical Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with implant or delivery related serious adverse events at 30 days Number of patients with implant or delivery related serious adverse events at 30 days 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT04919980 - TVMR With the Innovalve System Trial - Early Feasibility Study Phase 1
Recruiting NCT05688514 - TVMR With the Innovalve System Trial - First In Human Israel N/A
Recruiting NCT05010746 - TVMR With the Innovalve System Trial - Pilot Study in Italy N/A
Active, not recruiting NCT02718001 - Edwards EVOQUE Eos MISCEND Study N/A
Recruiting NCT05682066 - TVMR With the Innovalve System Trial - Pilot in Georgia N/A